Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. (NASDAQ: STIM) is a commercial stage medical technology and healthcare company focused on neurohealth and psychiatric disorders, and its news flow reflects this focus. The company develops and markets the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment used in office-based settings, and operates Greenbrook TMS treatment centers across the United States. News about Neuronetics often centers on clinical use of NeuroStar TMS, payer coverage decisions, and developments at its Greenbrook clinics.
Investors following STIM news can expect regular updates on quarterly financial and operating results, as the company reports revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue. Press releases also cover changes to its capital structure and credit facilities, such as amendments to its agreement with Perceptive Credit Holdings IV, LP, as well as at-the-market equity offerings and related capital-raising activities.
Company announcements frequently highlight health policy and reimbursement milestones, including expanded coverage for TMS therapy by New York State Medicaid and TRICARE West for specific patient populations with major depressive disorder. Neuronetics also reports on partnerships and agreements that expand access to NeuroStar TMS, such as an exclusive three-year collaboration with Elite DNA Behavioral Health, under which Neuronetics becomes the sole provider of TMS devices across that network and offers operational and patient-support services using the Greenbrook platform.
Additional STIM news items include participation in investor conferences, leadership and executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and publications of real-world clinical data from the NeuroStar outcomes databases. For readers tracking Neuronetics, this news page aggregates these developments so they can monitor financial performance, payer coverage trends, clinical evidence, and corporate actions related to NeuroStar TMS and Greenbrook treatment centers.
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) plans to release its Q3 2022 financial results on November 8, 2022, prior to market open. A conference call will follow at 8:30 a.m. ET to discuss the results, with a live webcast available. Neuronetics focuses on improving mental health through its NeuroStar Advanced Therapy, a non-invasive treatment for mood disorders like major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). NeuroStar has delivered over 4.8 million treatments and is backed by extensive clinical data.
Neuronetics (NASDAQ: STIM) has announced updates to its TrakStar platform to improve the patient management experience for NeuroStar providers. These enhancements streamline patient identification and re-treatment processes, supporting clinicians in managing treatment for drug-resistant depression. The upgrades include a simplified interface, automated patient candidate generation through the PHQ-10 tool, and improved benefits investigation integration. This marks the third enhancement of the TrakStar platform in 2022, reflecting Neuronetics’ ongoing commitment to innovation and support for mental health treatment.
Neuronetics announced the grand opening of NeuroStar University in Charlotte, North Carolina, the first training center in the TMS industry aimed at enhancing best practices for mental health treatment.
This facility will provide comprehensive education to help practices deliver optimal outcomes with NeuroStar Advanced Therapy. The curriculum includes Learn, Connect, and Grow components to enhance treatment quality for patients with drug-resistant depression.
Currently, NeuroStar University offers free two-day classes for existing practices.
Neuronetics, Inc. (NASDAQ: STIM) has granted inducement awards to 12 new non-executive employees, complying with NASDAQ Listing Rule 5635(c)(4). A total of 55,680 Restricted Stock Units (RSUs) were awarded, with vesting occurring in three equal installments over three years, contingent on continued service. The RSUs are part of the Neuronetics 2020 Inducement Plan. As a leader in neuroscience and TMS treatment, Neuronetics aims to enhance life quality for those with neurohealth disorders, including major depressive disorder.
Neuronetics (NASDAQ: STIM) reported Q2 2022 revenue of $16.3 million, exceeding guidance of $15.0 million to $16.0 million. This marks a 15% increase from Q2 2021, driven by a 70% rise in NeuroStar System sales, achieving a record 59 systems sold. Operationally, the company secured FDA clearance for treating OCD and anxious depression, and forged a long-term partnership with Alleviant Health Centers. However, net loss rose to $10.4 million, and international revenues fell by 50%. For 2022, revenue guidance is set between $60.0 million and $62.0 million.
MALVERN, Pa., July 28, 2022 - Neuronetics (NASDAQ: STIM), a medical technology company, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 11:30 am ET. CEO Keith Sullivan and CFO Steve Furlong will lead the presentation, which will be available via a live audio webcast on the company's investor relations page. Neuronetics, known for its NeuroStar® Advanced Therapy system, specializes in treatments for neurological disorders and aims to enhance life quality for patients with mental health conditions through innovative, FDA-cleared solutions.
Neuronetics (NASDAQ: STIM) announced a partnership with Alleviant Health Centers to expand access to its NeuroStar Advanced Therapy for mental health. This agreement makes Neuronetics the exclusive supplier of transcranial magnetic stimulation (TMS) equipment to Alleviant, with six NeuroStar systems to be delivered in 2022. NeuroStar, a proven non-drug treatment for major depressive disorder (MDD), has delivered over 4.5 million treatments with an 83% response rate. Alleviant aims to enhance patient care by upgrading its TMS devices, highlighting the synergy in improving mental health treatment.
MALVERN, Pa., July 19, 2022 (GLOBE NEWSWIRE) -- Neuronetics, focused on neurohealth disorders, will release its second quarter 2022 financial results before market open on August 2, 2022. A conference call to discuss the results will take place at 8:30 a.m. Eastern Time, accessible via webcast. Neuronetics is a leader in TMS therapy, with over 4.3 million treatments delivered for major depressive disorder. Their NeuroStar® system is FDA-cleared and emphasizes the importance of mental health, aiming to improve patients' quality of life.
Summary not available.
Neuronetics, Inc. (NASDAQ: STIM), a leader in non-invasive medical technology for neurological disorders, has announced that CEO Keith Sullivan and CFO Steve Furlong will present at the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 2:20 PM ET. The presentation will be accessible via a live audio webcast on the company's investor relations website, with a replay available for 90 days. Neuronetics is renowned for its NeuroStar® Advanced Therapy, a leading TMS treatment for depression, with over 4.3 million procedures performed to date.